Mingqing Zhou, Yannis Yan Liang, Sizhi Ai, Hongliang Feng, Yujing Zhou, Yaping Liu, Jihui Zhang, Fujun Jia, Binbin Lei
{"title":"加速计测量的睡眠时间与心血管疾病和心血管疾病死亡率的关系","authors":"Mingqing Zhou, Yannis Yan Liang, Sizhi Ai, Hongliang Feng, Yujing Zhou, Yaping Liu, Jihui Zhang, Fujun Jia, Binbin Lei","doi":"10.1093/sleep/zsae157","DOIUrl":null,"url":null,"abstract":"<p><strong>Study objectives: </strong>This study aimed to determine the associations between accelerometer-measured sleep durations and the risks of incident cardiovascular disease (CVD) and CVD-related mortality.</p><p><strong>Methods: </strong>A total of 92 261 participants (mean age: 62.4 ± 7.8 years, 56.4% female) were included in UK Biobank between 2013 and 2015. Average daily sleep durations were measured using wrist-worn accelerometers over a 7-day period. Sleep durations were categorized as <7 hours/day, 7-9 hours/day (reference), and >9 hours/day. The incidence of CVD and CVD-related mortality were ascertained by hospital records and death registries.</p><p><strong>Results: </strong>During a median follow-up period of 7.0 years, a total of 13 167 participants developed CVD, and 1079 participants died of CVD. Compared with a sleep duration 7-9 hours/day, an accelerometer-measured sleep duration <7 hours/day but not >9 hours/day was associated with higher risks of incident CVD (HR 1.06, 95% CI: 1.02 to 1.10), CVD-related mortality (HR 1.29, 95% CI: 1.14 to 1.47), coronary heart disease (HR 1.11, 95% CI: 1.03 to 1.19), myocardial infarction (HR 1.14, 95% CI: 1.03 to 1.27), heart failure (HR 1.20, 95% CI: 1.08 to 1.34), and atrial fibrillation (HR 1.15, 95% CI: 1.07 to 1.24). A curvilinear dose‒response pattern was observed between accelerometer-measured sleep durations and incident CVD (poverall < .001), with L-shaped associations found for incident CVD and CVD-related mortality.</p><p><strong>Conclusions: </strong>An accelerometer-measured sleep duration of <7 hours/day but not >9 hours/day was associated with elevated risks of incident CVD and CVD-related mortality. Maintaining adequate sleep may help promote cardiovascular health.</p>","PeriodicalId":22018,"journal":{"name":"Sleep","volume":null,"pages":null},"PeriodicalIF":5.6000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Associations of accelerometer-measured sleep duration with incident cardiovascular disease and cardiovascular mortality.\",\"authors\":\"Mingqing Zhou, Yannis Yan Liang, Sizhi Ai, Hongliang Feng, Yujing Zhou, Yaping Liu, Jihui Zhang, Fujun Jia, Binbin Lei\",\"doi\":\"10.1093/sleep/zsae157\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Study objectives: </strong>This study aimed to determine the associations between accelerometer-measured sleep durations and the risks of incident cardiovascular disease (CVD) and CVD-related mortality.</p><p><strong>Methods: </strong>A total of 92 261 participants (mean age: 62.4 ± 7.8 years, 56.4% female) were included in UK Biobank between 2013 and 2015. Average daily sleep durations were measured using wrist-worn accelerometers over a 7-day period. Sleep durations were categorized as <7 hours/day, 7-9 hours/day (reference), and >9 hours/day. The incidence of CVD and CVD-related mortality were ascertained by hospital records and death registries.</p><p><strong>Results: </strong>During a median follow-up period of 7.0 years, a total of 13 167 participants developed CVD, and 1079 participants died of CVD. Compared with a sleep duration 7-9 hours/day, an accelerometer-measured sleep duration <7 hours/day but not >9 hours/day was associated with higher risks of incident CVD (HR 1.06, 95% CI: 1.02 to 1.10), CVD-related mortality (HR 1.29, 95% CI: 1.14 to 1.47), coronary heart disease (HR 1.11, 95% CI: 1.03 to 1.19), myocardial infarction (HR 1.14, 95% CI: 1.03 to 1.27), heart failure (HR 1.20, 95% CI: 1.08 to 1.34), and atrial fibrillation (HR 1.15, 95% CI: 1.07 to 1.24). A curvilinear dose‒response pattern was observed between accelerometer-measured sleep durations and incident CVD (poverall < .001), with L-shaped associations found for incident CVD and CVD-related mortality.</p><p><strong>Conclusions: </strong>An accelerometer-measured sleep duration of <7 hours/day but not >9 hours/day was associated with elevated risks of incident CVD and CVD-related mortality. Maintaining adequate sleep may help promote cardiovascular health.</p>\",\"PeriodicalId\":22018,\"journal\":{\"name\":\"Sleep\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sleep\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/sleep/zsae157\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/sleep/zsae157","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
Associations of accelerometer-measured sleep duration with incident cardiovascular disease and cardiovascular mortality.
Study objectives: This study aimed to determine the associations between accelerometer-measured sleep durations and the risks of incident cardiovascular disease (CVD) and CVD-related mortality.
Methods: A total of 92 261 participants (mean age: 62.4 ± 7.8 years, 56.4% female) were included in UK Biobank between 2013 and 2015. Average daily sleep durations were measured using wrist-worn accelerometers over a 7-day period. Sleep durations were categorized as <7 hours/day, 7-9 hours/day (reference), and >9 hours/day. The incidence of CVD and CVD-related mortality were ascertained by hospital records and death registries.
Results: During a median follow-up period of 7.0 years, a total of 13 167 participants developed CVD, and 1079 participants died of CVD. Compared with a sleep duration 7-9 hours/day, an accelerometer-measured sleep duration <7 hours/day but not >9 hours/day was associated with higher risks of incident CVD (HR 1.06, 95% CI: 1.02 to 1.10), CVD-related mortality (HR 1.29, 95% CI: 1.14 to 1.47), coronary heart disease (HR 1.11, 95% CI: 1.03 to 1.19), myocardial infarction (HR 1.14, 95% CI: 1.03 to 1.27), heart failure (HR 1.20, 95% CI: 1.08 to 1.34), and atrial fibrillation (HR 1.15, 95% CI: 1.07 to 1.24). A curvilinear dose‒response pattern was observed between accelerometer-measured sleep durations and incident CVD (poverall < .001), with L-shaped associations found for incident CVD and CVD-related mortality.
Conclusions: An accelerometer-measured sleep duration of <7 hours/day but not >9 hours/day was associated with elevated risks of incident CVD and CVD-related mortality. Maintaining adequate sleep may help promote cardiovascular health.
期刊介绍:
SLEEP® publishes findings from studies conducted at any level of analysis, including:
Genes
Molecules
Cells
Physiology
Neural systems and circuits
Behavior and cognition
Self-report
SLEEP® publishes articles that use a wide variety of scientific approaches and address a broad range of topics. These may include, but are not limited to:
Basic and neuroscience studies of sleep and circadian mechanisms
In vitro and animal models of sleep, circadian rhythms, and human disorders
Pre-clinical human investigations, including the measurement and manipulation of sleep and circadian rhythms
Studies in clinical or population samples. These may address factors influencing sleep and circadian rhythms (e.g., development and aging, and social and environmental influences) and relationships between sleep, circadian rhythms, health, and disease
Clinical trials, epidemiology studies, implementation, and dissemination research.